Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 14(Suppl. 5), v1–v49 (2012).
  MedlineGoogle Scholar
• 2 Jansen MHA, van Vuurden DG, Vandertop WP, Kaspers GJL. Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat. Rev. 38(1), 27–35 (2012).
  Medline CASGoogle Scholar
• 3 Warren KE, Killian K, Suuriniemi M, Wang Y, Quezado M, Meltzer PS. Genomic aberrations in pediatric diffuse intrinsic pontine gliomas. Neuro Oncol. 14(3), 326–332 (2012).
  Medline CASGoogle Scholar
• 4 Sturm D, Bender S, Jones DTW et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat. Rev. Cancer 14(2), 92–107 (2014).• Hallmark genetic abnormalities associated with pediatric and adult glioblastoma are summarized, with discussion about molecular subtypes, DNA methylation profiling, structural variations including copy number aberrations and genomic rearrangements, complex interplay between genome and epigenome, tumor heterogeneity, and novel treatment strategies.
  Medline CASGoogle Scholar
• 5 Wu G, Diaz AK, Paugh BS et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat. Genet. 46(5), 444–450 (2014).
  Medline CASGoogle Scholar
• 6 Barkovich AJ, Krischer J, Kun LE et al. Brain stem gliomas: a classification system based on magnetic resonance imaging. Pediatr. Neurosurg. 16(2), 73–83 (1990).
  MedlineGoogle Scholar
• 7 Fischbein NJ, Prados MD, Wara W, Russo C, Edwards MS, Barkovich AJ. Radiologic classification of brain stem tumors: correlation of magnetic resonance imaging appearance with clinical outcome. Pediatr. Neurosurg. 24(1), 9–23 (1996).
  Medline CASGoogle Scholar
• 8 Albright AL, Packer RJ, Zimmerman R, Rorke LB, Boyett J, Hammond GD. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer Group. Neurosurgery 33(6), 1026–1029; discussion 1029–1030 (1993).
  Medline CASGoogle Scholar
• 9 Puget S, Blauwblomme T, Grill J. Is biopsy safe in children with newly diagnosed diffuse intrinsic pontine glioma? Am. Soc. Clin. Oncol. Educ. Book 629–633 (2012).
  MedlineGoogle Scholar
• 10 Geoerger B, Hargrave D, Thomas F et al. Innovative therapies for children with cancer pediatric Phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol. 13(1), 109–118 (2011).
  Medline CASGoogle Scholar
• 11 Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat. Genet. 46(5), 462–466 (2014).
  Medline CASGoogle Scholar
• 12 Taylor KR, Mackay A, Truffaux N et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat. Genet. 46(5), 457–461 (2014).• Recurrent activating ACVR1 mutations were identified in approximately 20% of diffuse intrinsic pontine gliomas (DIPGs), analogous to mutations found in fibrodysplasia ossificans progressiva. These mutations also constitutively activate the BMP-TGF-β signaling pathway, thereby offering possible new therapeutic targets.
  Medline CASGoogle Scholar
• 13 Khuong-Quang D-A, Buczkowicz P, Rakopoulos P et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 124(3), 439–447 (2012).
  Medline CASGoogle Scholar
• 14 Walker DA, Liu J, Kieran M et al. A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. Neuro. Oncol. 15(4), 462–468 (2013).
  MedlineGoogle Scholar
• 15 Kieran MW. Time to rethink the unthinkable: upfront biopsy of children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). Pediatr. Blood Cancer (2014).
  Google Scholar
• 16 Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 7(3), 241–248 (2006).
  MedlineGoogle Scholar
• 17 Packer RJ, Littman PA, Sposto RM et al. Results of a pilot study of hyperfractionated radiation therapy for children with brain stem gliomas. Int. J. Radiat. Oncol. Biol. Phys. 13(11), 1647–1651 (1987).
  Medline CASGoogle Scholar
• 18 Freeman CR, Krischer JP, Sanford RA et al. Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. Int. J. Radiat. Oncol. Biol. Phys. 27(2), 197–206 (1993).
  Medline CASGoogle Scholar
• 19 Mandell LR, Kadota R, Freeman C et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group Phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 43(5), 959–964 (1999).
  Medline CASGoogle Scholar
• 20 Kretschmar CS, Tarbell NJ, Barnes PD, Krischer JP, Burger PC, Kun L. Pre-irradiation chemotherapy and hyperfractionated radiation therapy 66 Gy for children with brain stem tumors. A Phase II study of the Pediatric Oncology Group, Protocol 8833. Cancer 72(4), 1404–1413 (1993).
  Medline CASGoogle Scholar
• 21 Packer RJ, Boyett JM, Zimmerman RA et al. Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas. A Childrens Cancer Group Phase I/II Trial. Cancer 72(4), 1414–1421 (1993).
  Medline CASGoogle Scholar
• 22 Lewis J, Lucraft H, Gholkar A. UKCCSG study of accelerated radiotherapy for pediatric brain stem gliomas. United Kingdom Childhood Cancer Study Group. Int. J. Radiat. Oncol. Biol. Phys. 38(5), 925–929 (1997).
  Medline CASGoogle Scholar
• 23 Janssens GO, Jansen MH, Lauwers SJ et al. Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis. Int. J. Radiat. Oncol. Biol. Phys. 85(2), 315–320 (2013).
  MedlineGoogle Scholar
• 24 Janssens GORJ, Gidding CEM, Van Lindert EJ et al. The role of hypofractionation radiotherapy for diffuse intrinsic brainstem glioma in children: a pilot study. Int. J. Radiat. Oncol. Biol. Phys. 73(3), 722–726 (2009).
  MedlineGoogle Scholar
• 25 Zaghloul MS, Eldebawy E, Ahmed S et al. Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): a randomized controlled trial. Radiother. Oncol. 111(1), 35–40 (2014).
  MedlineGoogle Scholar
• 26 Becher OJ, Hambardzumyan D, Walker TR et al. Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res. 70(6), 2548–2557 (2010).
  Medline CASGoogle Scholar
• 27 Paugh BS, Zhu X, Qu C et al. Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. Cancer Res. 73(20), 6219–6229 (2013).
  Medline CASGoogle Scholar
• 28 Zarghooni M, Bartels U, Lee E et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J. Clin. Oncol. 28(8), 1337–1344 (2010).•• Comprehensive high-resolution genomic analysis was performed in a small cohort of biopsy and post-mortem DIPGs, revealing distinct copy number abnormalities in DIPG as compared with pediatric supratentorial high-grade astrocytomas. Gains in PDGFRA were seen in a third of DIPGs; defects in DNA-repair pathways and low-level gains in PARP1 were also identified, suggesting additional potential therapeutic targets.
  Medline CASGoogle Scholar
• 29 Paugh BS, Broniscer A, Qu C et al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J. Clin. Oncol. 29(30), 3999–4006 (2011).•• Focal amplifications of genes involved in cell-cycle regulation and in the receptor tyrosine kinase-Ras-PI3K signaling pathway were observed in one-third and half of DIPGs, respectively, suggesting that targeted inhibition of cell-cycle regulatory proteins and receptor tyrosine kinases may be useful treatment strategies in DIPG.
  Medline CASGoogle Scholar
• 30 Paugh BS, Qu C, Jones C et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J. Clin. Oncol. 28(18), 3061–3068.
  MedlineGoogle Scholar
• 31 Broniscer A, Baker SD, Wetmore C et al. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin. Cancer Res. 19(11), 3050–3058 (2013).
  Medline CASGoogle Scholar
• 32 Wetmore C, Broniscer A, Turner D, Al E. First-in-pediatrics Phase I study of crenolanib besylate (CP-868,596–526) administered during and after radiation therapy (RT) in newly diagnosed diffuse intrinsic pontine glioma (DIPG) and recurrent high-grade glioma (HGG). J. Clin. Oncol. 32(5S), Abstract 10064 (2014).
  Google Scholar
• 33 Chen Y, Agarwal S, Shaik NM, Chen C, Yang Z, Elmquist WF. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J. Pharmacol. Exp. Ther. 330(3), 956–963 (2009).
  Medline CASGoogle Scholar
• 34 Lagas JS, van Waterschoot RAB, van Tilburg VACJ et al. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin. Cancer Res. 15(7), 2344–2351 (2009).
  Medline CASGoogle Scholar
• 35 Buczkowicz P, Hoeman C, Rakopoulos P et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat. Genet. 46(5), 451–456 (2014).• Whole-genome sequencing, methylation, expression and copy number profiling revealed that DIPGs are comprised of three molecularly distinct subgroups: H3-K27M, silent and MYCN. Constitutively activating ACVR1 mutations were identified in 20% of DIPGs, suggesting the potential for novel targeted therapies.
  Medline CASGoogle Scholar
• 36 Kaplan FS, Xu M, Seemann P et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum. Mutat. 30(3), 379–390 (2009).
  Medline CASGoogle Scholar
• 37 Zadeh G, Aldape K. ACVR1 mutations and the genomic landscape of pediatric diffuse glioma. Nat. Genet. 46(5), 421–422 (2014).
  Medline CASGoogle Scholar
• 38 Nakahara Y, Katagiri T, Ogata N, Haga N. ACVR1 (587T>C) mutation in a variant form of fibrodysplasia ossificans progressiva: second report. Am. J. Med. Genet. A.1 64A(1), 220–224 (2014).
  Google Scholar
• 39 Morovvati Z, Morovvati S, Alishiri G, Moosavi SH, Ranjbar R, Bolouki Moghaddam Y. Detection in activin a receptor, type I (ACVR1) gene in fibrodysplasia ossificans progressiva in an Iranian family. Cell J. 16(1), 91–94 (2014).
  MedlineGoogle Scholar
• 40 Shore EM, Xu M, Feldman GJ et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat. Genet. 38(5), 525–527 (2006).
  Medline CASGoogle Scholar
• 41 Lee Y-C, Cheng C-J, Bilen MA et al. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res. 71(15), 5194–5203 (2011).
  Medline CASGoogle Scholar
• 42 Sanvitale CE, Kerr G, Chaikuad A et al. A new class of small molecule inhibitor of BMP signaling. PLoS ONE 8(4), e62721 (2013).
  Medline CASGoogle Scholar
• 43 Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J. Clin. Neurosci. 16(6), 748–754 (2009).
  Medline CASGoogle Scholar
• 44 Loew S, Schmidt U, Unterberg A, Halatsch M-E. The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. Anticancer Agents Med. Chem. 9(6), 703–715 (2009).
  Medline CASGoogle Scholar
• 45 Bredel M, Pollack IF, Hamilton RL, James CD. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin. Cancer Res. 5(7), 1786–1792 (1999).
  Medline CASGoogle Scholar
• 46 Sung T, Miller DC, Hayes RL, Alonso M, Yee H, Newcomb EW. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol. 10(2), 249–259 (2000).
  Medline CASGoogle Scholar
• 47 Li G, Mitra SS, Monje M et al. Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas. J. Neurooncol. 108(3), 395–402 (2012).
  Medline CASGoogle Scholar
• 48 Cabanas R, Saurez G, Alert J et al. Prolonged use of nimotuzumab in children with central nervous system tumors: safety and feasibility. Cancer Biother. Radiopharm. 29(4), 173–178 (2014).
  Medline CASGoogle Scholar
• 49 Massimino M, Biassoni V, Miceli R et al. Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J. Neurooncol. 118(2), 305–312 (2014).
  Medline CASGoogle Scholar
• 50 Wen PY, Chang SM, Lamborn KR et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro. Oncol. 16(4), 567–578 (2014).
  Medline CASGoogle Scholar
• 51 Del Vecchio CA, Li G, Wong AJ. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. Expert Rev. Vaccines 11(2), 133–144 (2012).
  Medline CASGoogle Scholar
• 52 Barton KL, Misuraca K, Cordero F et al. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. PLoS ONE 8(10), e77639 (2013).
  Medline CASGoogle Scholar
• 53 Fouladi M, Laningham F, Wu J et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J. Clin. Oncol. 25(30), 4806–4812 (2007).
  Medline CASGoogle Scholar
• 54 Fouladi M, Perentesis JP, Phillips CL et al. A Phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study. Pediatr. Blood Cancer 61(7), 1246–1251 (2014).
  Medline CASGoogle Scholar
• 55 Gil del Alcazar CR, Hardebeck MC, Mukherjee B et al. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin. Cancer Res. 20(5), 1235–1248 (2014).
  Medline CASGoogle Scholar
• 56 Saratsis AM, Kambhampati M, Snyder K et al. Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes. Acta Neuropathol. 127(6), 881–895 (2013).
  MedlineGoogle Scholar
• 57 Monje M, Mitra SS, Freret ME et al. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc. Natl Acad. Sci. USA 108(11), 4453–4458 (2011).
  Medline CASGoogle Scholar
• 58 Ruscetti T, Lehnert BE, Halbrook J et al. Stimulation of the DNA-dependent protein kinase by poly(ADP-ribose) polymerase. J. Biol. Chem. 273(23), 14461–14467 (1998).
  Medline CASGoogle Scholar
• 59 Schreiber V, Amé J-C, Dollé P et al. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J. Biol. Chem. 277(25), 23028–23036 (2002).
  Medline CASGoogle Scholar
• 60 Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin. Cancer Res. 13(5), 1383–1388 (2007).
  Medline CASGoogle Scholar
• 61 Cheng CL, Johnson SP, Keir ST et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol. Cancer Ther. 4(9), 1364–1368 (2005).
  Medline CASGoogle Scholar
• 62 Dungey FA, Löser DA, Chalmers AJ. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int. J. Radiat. Oncol. Biol. Phys. 72(4), 1188–1197 (2008).
  Medline CASGoogle Scholar
• 63 Russo AL, Kwon H-C, Burgan WE et al. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin. Cancer Res. 15(2), 607–612 (2009).
  Medline CASGoogle Scholar
• 64 Palma JP, Wang Y-C, Rodriguez LE et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin. Cancer Res. 15(23), 7277–7290 (2009).
  Medline CASGoogle Scholar
• 65 Caretti V, Hiddingh L, Lagerweij T et al. WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas. Mol. Cancer Ther. 12(2), 141–150 (2013).
  Medline CASGoogle Scholar
• 66 Mueller S, Hashizume R, Yang X et al. Targeting Wee1 for the treatment of pediatric high-grade gliomas. Neuro. Oncol. 16(3), 352–360 (2013).
  MedlineGoogle Scholar
• 67 Mir SE, De Witt Hamer PC, Krawczyk PM et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 18(3), 244–257 (2010).
  Medline CASGoogle Scholar
• 68 Bulavin D V, Demidov ON, Saito S et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat. Genet. 31(2), 210–215 (2002).
  Medline CASGoogle Scholar
• 69 Zhang L, Chen LH, Wan H et al. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nat. Genet. 46(7), 726–730 (2014).
  Medline CASGoogle Scholar
• 70 Yagi H, Chuman Y, Kozakai Y et al. A small molecule inhibitor of p53-inducible protein phosphatase PPM1D. Bioorg. Med. Chem. Lett. 22(1), 729–732 (2012).
  Medline CASGoogle Scholar
• 71 Gilmartin AG, Faitg TH, Richter M et al. Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction. Nat. Chem. Biol. 10(3), 181–187 (2014).
  Medline CASGoogle Scholar
• 72 Wu G, Broniscer A, McEachron TA et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 44(3), 251–253 (2012).• In this seminal study, whole-genome and targeted sequencing was performed in a cohort of DIPGs, revealing that more than two-thirds of DIPGs contained a mutation in H3F3A encoding histone H3.3.
  Medline CASGoogle Scholar
• 73 Lewis PW, Müller MM, Koletsky MS et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340(6134), 857–861 (2013).
  Medline CASGoogle Scholar
• 74 Chan K-M, Fang D, Gan H et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 27(9), 985–990 (2013).
  Medline CASGoogle Scholar
• 75 Sturm D, Witt H, Hovestadt V et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22(4), 425–437 (2012).
  Medline CASGoogle Scholar
• 76 Brennan CW, Verhaak RGW, McKenna A et al. The somatic genomic landscape of glioblastoma. Cell 155(2), 462–477 (2013).
  Medline CASGoogle Scholar
• 77 Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 342(6165), 1432–1433 (2013).
  Medline CASGoogle Scholar
• 78 Pollack IF, Jakacki RI, Butterfield LH et al. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J. Clin. Oncol. 32(19), 2050–2058 (2014).
  Medline CASGoogle Scholar
• 79 Iwami K, Shimato S, Ohno M et al. Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy 14(6), 733–742 (2012).
  Medline CASGoogle Scholar
• 80 Akiyama Y, Oshita C, Kume A et al. α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a Phase I clinical trial. BMC Cancer 12, 623 (2012).
  Medline CASGoogle Scholar
• 81 Krebs S, Chow KKH, Yi Z et al. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein-chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1. Cytotherapy 16(8), 1121–3111 (2014).
  Medline CASGoogle Scholar
• 82 Lee HW, Singh TD, Lee S-W et al. Evaluation of therapeutic effects of natural killer (NK) cell-based immunotherapy in mice using in vivo apoptosis bioimaging with a caspase-3 sensor. FASEB J. 28(7), 2932–2941 (2014).
  Medline CASGoogle Scholar
• 83 Agarwalla P, Barnard Z, Fecci P, Dranoff G, Curry WT. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J. Immunother. 35(5), 385–389 (2012).
  Medline CASGoogle Scholar
• 84 Allhenn D, Boushehri MAS, Lamprecht A. Drug delivery strategies for the treatment of malignant gliomas. Int. J. Pharm. 436(1–2), 299–310 (2012).
  Medline CASGoogle Scholar
• 85 Bidros DS, Vogelbaum MA. Novel drug delivery strategies in neuro-oncology. Neurotherapeutics 6(3), 539–546 (2009).
  Medline CASGoogle Scholar
• 86 Wolfe J, Grier HE, Klar N et al. Symptoms and suffering at the end of life in children with cancer. N. Engl. J. Med. 342(5), 326–333 (2000).
  Medline CASGoogle Scholar
• 87 Van der Geest IMM, Darlington A-SE, Streng IC, Michiels EMC, Pieters R, van den Heuvel-Eibrink MM. Parents’ experiences of pediatric palliative care and the impact on long-term parental grief. J. Pain Symptom Manage. 47(6), 1043–1053 (2014).
  MedlineGoogle Scholar
• 88 Zelcer S, Cataudella D, Cairney AEL, Bannister SL. Palliative care of children with brain tumors: a parental perspective. Arch. Pediatr. Adolesc. Med. 164(3), 225–230 (2010).
  MedlineGoogle Scholar
• 89 Friebert S, Osenga K. Pediatric Palliative Care Referral Criteria. Center to Advance Palliative Care. (2009). www.sccm.org/Communications/Critical-Connections/Archives/Pages/Palliative-Care-in-the-Pediatric-Intensive-Care-Unit.aspx.
  Google Scholar
• 90 Levine D, Lam CG, Cunningham MJ et al. Best practices for pediatric palliative cancer care: a primer for clinical providers. J. Support. Oncol. 11(3), 114–125 (2013).
  MedlineGoogle Scholar
• 91 Patel AP, Tirosh I, Trombetta JJ et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344(6190), 1396–1401 (2014).
  Medline CASGoogle Scholar
• 92 Kris MG, Johnson BE, Berry LD et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311(19), 1998–2006 (2014).
  Medline CASGoogle Scholar
• 93 Skog J, Würdinger T, van Rijn S et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10(12), 1470–1476 (2008).
  Medline CASGoogle Scholar
• 94 Atkinson JM, Shelat AA, Carcaboso AM et al. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 20(3), 384–399 (2011).
  Medline CASGoogle Scholar
• 95 Morfouace M, Shelat A, Jacus M et al. Pemetrexed and gemcitabine as combination therapy for the treatment of group 3 medulloblastoma. Cancer Cell 25(4), 516–529 (2014).
  Medline CASGoogle Scholar